Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and Safety of an Increased-dose of Dexamethasone in Patients Receiving Fosaprepitant Chemotherapy in Japan

  • Kumagai, Hozumi (Department of Hematology and Oncology, Kyushu University Hospital) ;
  • Kusaba, Hitoshi (Department of Hematology and Oncology, Kyushu University Hospital) ;
  • Okumura, Yuta (Department of Hematology and Oncology, Kyushu University Hospital) ;
  • Komoda, Masato (Department of Hematology and Oncology, Kyushu University Hospital) ;
  • Nakano, Michitaka (Department of Hematology and Oncology, Kyushu University Hospital) ;
  • Tamura, Shingo (Department of Hematology and Oncology, Kyushu University Hospital) ;
  • Uchida, Mayako (Department of Pharmacy, Kyushu University Hospital) ;
  • Nagata, Kenichiro (Department of Pharmacy, Kyushu University Hospital) ;
  • Arita, Shuji (Department of Hematology and Oncology, Kyushu University Hospital) ;
  • Ariyama, Hiroshi (Department of Hematology and Oncology, Kyushu University Hospital) ;
  • Takaishi, Shigeo (Center for Advanced Medical Innovation, Kyushu University) ;
  • Akashi, Koichi (Department of Hematology and Oncology, Kyushu University Hospital) ;
  • Baba, Eishi (Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University)
  • Published : 2014.01.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Antiemetic triplet therapy including dexamethasone (DEX) is widely used for patients receiving highly emetogenic chemotherapy (HEC). In Japan, the appropriate dose of DEX has not been established for this combination. Materials and Methods: To assess the efficacy and safety of increased-dose DEX, we retrospectively examined patients receiving HEC with antiemetic triplet therapy. Results: Twenty-four patients (fosaprepitant group) were given an increased-dose of DEX (average total dose: 45.8mg), fosaprepitant, and 5-HT3 antagonist. A lower-dose of DEX (33.6mg), oral aprepitant, and 5-HT3 antagonist were administered to the other 48 patients (aprepitant group). The vomiting control rates in the fosaprepitant and aprepitant groups were 100% and 85.4% in the acute phase, and were 75.0% and 64.6% in the delayed phase. The incidences of toxicity were similar comparing the two groups. Conclusions: Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC.

Keywords

References

  1. Aapro MS, Grunberg SM, Manikhas GM, et al (2006). A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapyinduced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol, 17, 1441-9. https://doi.org/10.1093/annonc/mdl137
  2. del Giglio A, Soares HP, Caparroz C, Castro PC (2000). Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting-Results of a meta-analysis of randomized controlled trials. Cancer, 89, 2301-8. https://doi.org/10.1002/1097-0142(20001201)89:11<2301::AID-CNCR19>3.0.CO;2-6
  3. F. Roila, J. Herrstedt, M. Aapro, et al (2010). Guideline update for MASCC and ESMO in the prevention of chemotherapyand radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol, 21, 232-43. https://doi.org/10.1093/annonc/mdp300
  4. Goedhals L, Heron JF, Kleisbauer JP, Pagani O, Sessa C (1998). Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: A double-blind, placebo-controlled, comparative study. Ann Oncol, 9, 661-6. https://doi.org/10.1023/A:1008256115221
  5. Grunberg S, Chua D, Maru A, et al (2011). Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol-EASE. J Clin Oncol, 29, 1495-501. https://doi.org/10.1200/JCO.2010.31.7859
  6. Hale JJ, Mills SG, MacCoss M, et al (2000). Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J Med Chem, 43, 1234-41. https://doi.org/10.1021/jm990617v
  7. Hesketh PJ, Grunberg SM, Gralla RJ, et al (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin The Aprepitant Protocol 052 Study Group. J Clin Oncol, 21, 4112-9. https://doi.org/10.1200/JCO.2003.01.095
  8. Italian Group for Antiemetic Research (1998). Doubleblind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol, 16, 2937-42.
  9. John PA. Ioannidis, Paul JH, Joseph L (2000). Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence. J Clin Oncol, 18, 3409-22.
  10. Kris MG, Gralla RJ, Tyson LB, et al (1989). Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol, 7, 108-14.
  11. McCrea JB, Majumdar AK, Goldberg MR, et al (2003). Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther, 74, 17-24. https://doi.org/10.1016/S0009-9236(03)00066-3
  12. Saito H, Yoshizawa H, Yoshimori K, et al (2013). Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol, 24, 1067-73. https://doi.org/10.1093/annonc/mds541

Cited by

  1. Anticipatory nausea in animal models: a review of potential novel therapeutic treatments vol.232, pp.8, 2014, https://doi.org/10.1007/s00221-014-3942-9
  2. Dexamethasone Disrupts Cytoskeleton Organization and Migration of T47D Human Breast Cancer Cells by Modulating the AKT/mTOR/RhoA Pathway vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10245